Fusidate sodium
Highest phase reached
Approved
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Fusidate sodium
- Molecular weight
- 538.7
- Structure (SMILES)
- CC(=O)O[C@H]1C[C@@]2(C)[C@@H](C[C@@H](O)[C@H]3[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@@H]4CC[C@@]32C)/C1=C(\CCC=C(C)C)C(=O)[O-].[Na+]
- fucidine
- Fucidine
- fucidin
- Fucidin
- fucidin leo
- Fucidin leo
- fucidin ointment
- Fucidin Ointment
- Fucidin® cream
- fusidate sodium
- Fusidate sodium
- Fusidate sodium [USAN]
- Fusidate sodium [WHO-DD]
- fusidate sodium usan
- fusidate sodium who dd
- fusidic acid sodium salt
- Fusidic acid sodium salt
- Fusidic acid sodium salt [MI]
- fusidic acid sodium salt mi
- Fusidic acid, sodium salt
- sodium 3α 11α 16β trihydroxy 29 nor 8α 9β 13α 14β dammara 17 20 24 dien 21 oate 16 acetate
- Sodium 3α,11α,16β-trihydroxy-29-nor-8α,9β,13α,14β-dammara-17(20),24-dien-21-oate 16-acetate
- sodium fusidate
- Sodium fusidate
- Sodium Fusidate
- Sodium fusidate [EP MONOGRAPH]
- Sodium fusidate [JAN]
And 11 more, listed on the interactive page.
- CAS registry numbers
- 751-94-0
- ChEMBL ID
- CHEMBL1256987
- InChIKey
- HJHVQCXHVMGZNC-JCJNLNMISA-M
- PubChem compound IDs
- 23672955
- RxNorm IDs (RxCUI)
- 9874
- FDA ingredient codes (UNII)
- J7P3696BCQ
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- fusidic acid
- Type
- Synthetic organic
Mechanisms of action
- Mechanism
- Elongation factor G inhibitor
- Action type
- Inhibitor
- Target
- Elongation factor G
- Protein identifier
- P68790
Open Targets mechanisms
- Mechanism
- Elongation factor G inhibitor
- Action type
- Inhibitor
- Target
- Elongation factor G
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Diabetic Foot
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:1001459
- Subject identifier
- D017719
- Condition
- Cystic Fibrosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0009061
- Subject identifier
- D003550
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001459
- Condition identifier
- HP_0000964
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009061
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021178
- Event
- acute generalised exanthematous pustulosis
- Reports
- 3
- Reporting signal score
- 6.59175
- Event
- acute kidney injury
- Reports
- 8
- Reporting signal score
- 6.70328
- Event
- agranulocytosis
- Reports
- 4
- Reporting signal score
- 7.04195
- Event
- bilirubin conjugated increased
- Reports
- 3
- Reporting signal score
- 10.2867
- Event
- blood creatine phosphokinase increased
- Reports
- 7
- Reporting signal score
- 12.3359
- Event
- burns third degree
- Reports
- 3
- Reporting signal score
- 15.8631
- Event
- cataract
- Reports
- 12
- Reporting signal score
- 30.5468
- Event
- cholestasis
- Reports
- 15
- Reporting signal score
- 45.4906
- Event
- circulatory failure neonatal
- Reports
- 1
- Reporting signal score
- 6.84719
- Event
- dermatitis atopic
- Reports
- 12
- Reporting signal score
- 54.7154
- Event
- drug interaction
- Reports
- 13
- Reporting signal score
- 13.4645
- Event
- dyspepsia
- Reports
- 13
- Reporting signal score
- 28.2904
- Event
- dysphagia
- Reports
- 12
- Reporting signal score
- 20.1081
- Event
- eczema
- Reports
- 5
- Reporting signal score
- 10.6195
- Event
- eczema impetiginous
- Reports
- 1
- Reporting signal score
- 6.19363
- Event
- eosinophilia
- Reports
- 8
- Reporting signal score
- 20.4137
- Event
- fat necrosis
- Reports
- 4
- Reporting signal score
- 20.3335
- Event
- flat feet
- Reports
- 1
- Reporting signal score
- 7.01419
- Event
- gastroenteritis
- Reports
- 12
- Reporting signal score
- 38.7715
- Event
- gastrointestinal motility disorder
- Reports
- 3
- Reporting signal score
- 10.0608
- Event
- haematoma
- Reports
- 5
- Reporting signal score
- 9.18021
- Event
- immune reconstitution inflammatory syndrome
- Reports
- 5
- Reporting signal score
- 15.645
- Event
- jaundice
- Reports
- 13
- Reporting signal score
- 34.0678
- Event
- metabolic acidosis
- Reports
- 4
- Reporting signal score
- 6.17358
- Event
- muscular weakness
- Reports
- 14
- Reporting signal score
- 25.4268
And 22 more, listed on the interactive page.
- NCT02569541
- NCT02570490
- NCT03816618
- NCT05641298
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 104.06
- Calculated partition coefficient (ALogP)
- 5.67
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 5
- Heavy atoms
- 38
- Molecular formula
- C31H47NaO6
- Monoisotopic mass
- 538.32703350
- Natural product
- Yes
- Recorded assays
- 547
- Active assays
- 9
- Confirmatory
- Screening
- Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA.
- Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins.
Related records
Trials (28)
- A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis
- A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
- A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
- Chronic Pain Risk Associated With Menstrual Period Pain
- Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
- Effectiveness of Sodium Fusidate Ointment Compared to Petrolatum for Wound Healing Following Cauterization
- Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema
- Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
- Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
- Fucidin® Cream in the Treatment of Impetigo
- Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection
- Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia
- Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
- Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation
- Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
- Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
- Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis
- Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age
In development for (1)
- Cystic fibrosis Phase 2